Oppenheimer analyst Jeff Jones maintains MediWound (NASDAQ:MDWD) with a Outperform and lowers the

MediWound Ltd. (MDWD) Q2 2026 Earnings Call Transcript

MediWound NASDAQ: MDWD reported second-quarter 2026 revenue of $3.1 million, down from $5.7 million

MediWound (NASDAQ:MDWD) held its second-quarter earnings conference call on Thursday. Below is the c

MediWound (MDWD) came out with a quarterly loss of $0.77 per share versus the Zacks Consensus Estima

MediWound (NASDAQ:MDWD) reported quarterly losses of $(0.77) per share which missed the analyst cons

MediWound (NASDAQ:MDWD) affirms FY2026 sales outlook from $24.000 million-$26.000 million to $24.000

EscharEx ® Phase III VALUE Trial Advancing; Interim Assessment and Enrollment Completion Expected by

MediWound to Report Second Quarter 2026 Financial Results Conference Call and Webcast Scheduled for

Oppenheimer analyst Francois Brisebois maintains MediWound (NASDAQ:MDWD) with a Outperform and lo

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates MediWound (NASDAQ:MDWD) with a

MediWound Ltd. (MDWD) Q1 2026 Earnings Call Transcript

MediWound NASDAQ: MDWD reported a wider first-quarter loss and lower revenue compared with the prior

MediWound (MDWD) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estima

MediWound (NASDAQ:MDWD) affirms FY2026 sales outlook from $24.000 million-$26.000 million to $24.000

MediWound (NASDAQ:MDWD) reported quarterly losses of $(0.23) per share which beat the analyst consen

EscharEx ® Phase III VALUE trial advancing; interim assessment and enrollment completion expected by

MediWound to Report First Quarter 2026 Financial Results Conference Call and Webcast Scheduled for W

Surrozen (NASDAQ: SRZN - Get Free Report) and MediWound (NASDAQ: MDWD - Get Free Report) are both sm

Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement

MediWound to Present New EscharEx ® Data at Leading Wound Care Conferences   Data highlights mechani

Dyne Therapeutics (NASDAQ: DYN - Get Free Report) and MediWound (NASDAQ: MDWD - Get Free Report) are

MediWound Reports BARDA Contract Award to Vericel for NexoBrid ® Valued at up to $197 Million YAVNE,

MediWound Ltd. (MDWD) Q4 2025 Earnings Call Transcript

MediWound Files Annual Report on Form 20-F YAVNE, Israel, March 5 , 202 6 -- MediWound Ltd. (Nasdaq:

MediWound (MDWD) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estima

EscharEx ® Phase III VALUE trial advancing as planned Expanded NexoBrid ® manufacturing facility ope

MediWound to Report Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast

Shares of NIO Inc. (NYSE:NIO) fell sharply during Friday's session after the company disclosed t

Shares of Sharps Technology, Inc. (NASDAQ:STSS) rose sharply in today's pre-market trading after

Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarte

Biopharmaceutical company MediWound Ltd (NASDAQ: MDWD) reported that the U.S.

Companies Reporting Before The Bell • Golden Ocean Group (NASDAQ:GOGL) is likely to report quarterl

  Friday's session saw 225 companies set new 52-week lows.

  On Thursday, 283 companies set new 52-week lows.

  On Wednesday, 179 companies reached new 52-week lows.

Companies Reporting Before The Bell • Mainz Biomed (NASDAQ:MYNZ) is projected to report earnings fo

Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is projected to report earnings for

Companies Reporting Before The Bell • KVH Industries (NASDAQ:KVHI) is projected to report quarterly

Biopharma stocks were not immune to the broader market downturn seen for much of 2022.

  Tuesday's session saw 167 companies set new 52-week lows.